FDA
-
-
-
-
-
-
-
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
-
-
-
-
-
-
-
NANOBIOTIX 2020 Q4 and Annual Revenues
-
-
-
-
-
-
-
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
-
-
-
-
-
-
-
NANOBIOTIX Announces First Quarter 2020 Revenues
-
-
-
-
-
-
-
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
-
-
-
-
-
-
-
NANOBIOTIX Appoints New Chief Medical Officer as the Company Evolves after Achievement of European Market Approval
-
-
-
-
-
-
-
Nanobiotix 2018 Annual Results
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

